Remdesivir for Treatment of COVID-19: Combination of Pulmonary and IV Administration May Offer Aditional Benefit
- 26 May 2020
- journal article
- editorial
- Published by Springer Science and Business Media LLC in The AAPS Journal
- Vol. 22 (4), 1-6
- https://doi.org/10.1208/s12248-020-00459-8
Abstract
Remdesivir is one of the most promising drugs to treat COVID-19 based on the following facts: remdesivir has a broad-spectrum antiviral mechanism of action; it demonstrated in vitro activity against SARS-CoV-2 and in vivo efficacy in animal models against the similar coronavirus MERS-CoV; its safety profile has been tested in Ebola patients and in compassionate use in COVID-19 patients. Currently, remdesivir is being investigated in ten randomized controlled trials against COVID-19. The dose regimen of remdesivir is an IV loading dose of 200 mg on day 1 followed by daily IV maintenance doses of 100 mg for 5–9 days. Based on our data analysis, however, remdesivir with IV administration alone is unlikely to achieve excellent clinical efficacy. This analysis is based on the following observations: plasma exposures of remdesivir and its active metabolite are unlikely to be correlated with its clinical efficacy; remdesivir and its active metabolites are unlikely to be adequate in the lung to kill the SARS-CoV-2 virus. Even if remdesivir demonstrates benefits in the current randomized controlled trials, its efficacy may be limited. We suggest that a combination of an IV and pulmonary delivery dose regimen should be studied immediately to realize a potentially more effective antiviral therapy against COVID-19. Graphical abstractKeywords
This publication has 21 references indexed in Scilit:
- Different Nanoformulations Alter the Tissue Distribution of Paclitaxel, Which Aligns with Reported Distinct Efficacy and Safety ProfilesMolecular Pharmaceutics, 2018
- Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronavirusesScience Translational Medicine, 2017
- Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging VirusesPublished by American Chemical Society (ACS) ,2017
- Distinct biodistribution of doxorubicin and the altered dispositions mediated by different liposomal formulationsInternational Journal of Pharmaceutics, 2017
- Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeysNature, 2016
- Applications of Human Pharmacokinetic Prediction in First-in-Human Dose EstimationThe AAPS Journal, 2012
- Evolution of dry powder inhaler design, formulation, and performanceRespiratory Medicine, 2002
- Physiological Parameters in Laboratory Animals and HumansPharmaceutical Research, 1993
- Aerosolized ribavirin in the treatment of patients with respiratory syncytial virus diseaseThe Pediatric Infectious Disease Journal, 1987
- RIBAVIRIN SMALL-PARTICLE AEROSOL TREATMENT OF INFLUENZAThe Lancet, 1981